In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas 1
暂无分享,去创建一个
S. Vandenberg | D. Haas-Kogan | A. Nudelman | A. Rephaeli | M. Entin-Meer | Xiao-ding Yang | R. Lamborn
[1] K. Aldape,et al. Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.
[2] A. Nudelman,et al. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs , 2006, Investigational New Drugs.
[3] R. Stupp,et al. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. , 2006, Neurosurgical focus.
[4] S. Vandenberg,et al. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas , 2005, Molecular Cancer Therapeutics.
[5] Z. Malik,et al. In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer , 2005, International journal of cancer.
[6] S. Tucker,et al. Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity , 2005, Clinical Cancer Research.
[7] R. Blaheta,et al. Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies , 2005, Medicinal research reviews.
[8] K. Camphausen,et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid , 2005, International journal of cancer.
[9] H. Keer,et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. , 2004, Lung cancer.
[10] M. E. Robinson,et al. Favorable Neuroblastoma Genes and Molecular Therapeutics of Neuroblastoma , 2004, Clinical Cancer Research.
[11] P. Olive,et al. Phosphorylation of histone H2AX as a measure of radiosensitivity. , 2004, International journal of radiation oncology, biology, physics.
[12] A. Wozniak,et al. Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.
[13] C. Britten,et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] S. Vandenberg,et al. Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. , 2002, Neuro-oncology.
[15] A. Nudelman,et al. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). , 2001, Cancer research.
[16] R A Rifkind,et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.
[17] T. Tsuruo,et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Nudelman,et al. Novel anticancer prodrugs of butyric acid. 2. , 1992, Journal of medicinal chemistry.